CoDa Therapeutics' Nexagon indicates increased healing in patients with chronic venous leg ulcers.
M2 PHARMA-January 11, 2013-CoDa Therapeutics' Nexagon indicates increased healing in patients with chronic venous leg ulcers(C)2013 M2 COMMUNICATIONS
United States-based CoDa Therapeutics has announced that Nexagon was well tolerated and indicated an increase in complete healing in patients with chronic venous leg ulcers in the Phase 2b study.
It was reported yesterday that the results of the study support the development of Nexagon into Phase 3 registration trials. The UNC Limb Salvage/Wound Healing Centre medical director and University of North Carolina division of vascular surgery professor and chief, Dr. William Marston, stated that the company's Phase 2b clinical results indicate a well-designed and executed dosing phase study.
Marston said, 'This data will provide clear information to choose an optimal dose and patient profile to move to a pivotal clinical trial.'
((Comments on this story may be sent to email@example.com))